Immunogen Inc (DELISTED) (IMGN:DL)
31.23
0.00 (0.00%)
USD |
NASDAQ |
Feb 13, 16:00
Immunogen Research and Development Expense (Annual): 213.37M for Dec. 31, 2022
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2022 | 213.37M |
| December 31, 2021 | 151.12M |
| December 31, 2020 | 114.59M |
| December 31, 2019 | 114.52M |
| December 31, 2018 | 174.46M |
| December 31, 2017 | 139.74M |
| December 31, 2016 | 66.57M |
| June 30, 2016 | 148.08M |
| June 30, 2015 | 111.77M |
| June 30, 2014 | 106.96M |
| June 30, 2013 | 87.07M |
| June 30, 2012 | 69.19M |
| June 30, 2011 | 63.45M |
| June 30, 2010 | 50.28M |
| Date | Value |
|---|---|
| June 30, 2009 | 45.90M |
| June 30, 2008 | 60.01M |
| June 30, 2007 | 45.84M |
| June 30, 2006 | 40.91M |
| June 30, 2005 | 30.54M |
| June 30, 2004 | 21.69M |
| June 30, 2003 | 23.43M |
| June 30, 2002 | 17.69M |
| June 30, 2001 | 15.21M |
| June 30, 2000 | 8.878M |
| June 30, 1999 | 6.10M |
| June 30, 1998 | 6.60M |
| June 30, 1997 | 7.40M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
114.52M
Minimum
2019
213.37M
Maximum
2022
148.40M
Average
132.85M
Median
Research and Development Expense (Annual) Benchmarks
| AbbVie Inc | 7.675B |
| Pfizer Inc | 10.68B |
| Johnson & Johnson | 15.08B |
| Merck & Co Inc | 30.53B |
| Cerevel Therapeutics Holdings Inc | 334.64M |